Pyruvate is a valuable chemical intermediate in the production of fine chemicals used by agrochemical, pharmaceutical, and food industries. Current technology for production of pyruvic acid is based on conversion from tartaric acid and results in environmentally incompatible byproducts. An enzymatic approach to making pyruvate was developed by cloning the glycolate oxidase (GO) gene from spinach into Pichia pastoris (Payne, et al., (1995). High-level production of spinach glycolate oxidase in the methylotrophic yeast Pichia pastoris: Engineering a biocatalyst. Gene, 167(1-2), 215-219). GO is a flavoprotein (FMN dependent) which catalyzes the conversion of lactate to pyruvate with the equimolar production of hydrogen peroxide. Hydrogen peroxide can lower GO activity and make non-catalytic byproducts, so catalase was also cloned into P. pastoris to create a double transformant. Process development work was completed at the University of Iowa's Center for Biocatalysis and Bioprocessing. High-density P. pastoris fermentation (7.2 kg cells/L) was completed at the 100 L scale. Critical fermentation set-points were confirmed at 14 h glycerol feeding followed by methanol induction at 2 - 10 g/L for 30 h. After fermentation, these cells were permeabilized with benzalkonium chloride (BAC) to enable whole-cell biocatalysis and increase enzyme activity, yielding 100 U/g for GO. In 30 L enzyme reactions, permeabilized cells were recycled three times for over 92% conversion of 0.5 M lactate with an "enzyme to product" ratio of approximately 1:2 (Gough, et al., (2005). Production of pyruvate from lactate using recombinant Pichia pastoris cells as catalyst. Process Biochemistry, 40(8), 2597-2601). Though effective, the post-fermentation process for GO recovery involved several unit-operations, including multiple washing steps to remove residual BAC. The present work has focused on minimizing unit-operations by spray-drying the fermentation product to create a powdered biocatalyst. Optimal spray-drying conditions for the Buchi B-190 instrument were 150°C drying air, 15 mL/min liquid feed rate, and 600 mg cells/mL liquid feed. These conditions resulted in P. pastoris biocatalyst with activities of 80 - 100 U/g for GO and 180,000 - 220,000 U/g for catalase. The spray-dried cells retained nearly 100% of the enzyme activity compared to BAC treated cells as reported by Gough et al. Additionally, the spray-dried biocatalyst was stable at room temperature for 30 days, and no measurable enzyme leaching was observed. Then, P. pastoris was spray-dried under optimal conditions and tested for conversion of lactate to pyruvate for an improved "enzyme to product" ratio. Enzyme reaction optimization was done at the one-liter scale in DASGIP reactors. The DASGIP system contained four parallel reactors with control of temperature, pH, and dissolved oxygen. Other key variables included substrate loading, conducting the reaction in buffer or water, minimizing enzyme concentration, and maximizing the number of enzyme recycles. Optimal performance was achieved in water at pH 7.0 with an operating temperature of 25°C and 1.0 M substrate loading. Enzyme loading was at 12 g/L for the first two cycles, and subsequently, 2 - 3 g/L of fresh cells were added every alternate cycle to reach 15 cycles. Under these conditions, 75 - 95% conversion of lactate to pyruvate was accomplished for every 12 - 16 h reaction cycle. Based on these parameters, an "enzyme to product" ratio of 1:41 was achieved.

The influence of body size on metabolic rate, muscle enzyme activities, and the underlying patterns of mRNA for these enzymes were explored in an effort to explain the genetic basis of allometric variation in metabolic enzymes. Two pairs of sister species of centrarchid fishes were studied: black bass (largemouth bass, Micropterus salmoides and smallmouth bass, Micropterus dolomieui), and sunfish (pumpkinseed, Lepomis gibbosus and bluegill, Lepomis macrochirus). The goal was to assess the regulatory basis of both intraspecific and interspecific variation in relation to body size, as well as gain insights into the evolutionary constraints within lineages. Whole animal routine metabolic rate showed scaling coefficients not significantly different from 1, ranging from +0.87 to +0.96. However, there were significant effects of body size on the specific activities of oxidative and glycolytic enzymes. Mass-specific activity of the oxidative enzyme citrate synthase (CS) scaled negatively with body size in each species, with scaling coefficients ranging from -0.15 to -0.19 whereas the glycolytic enzyme pyruvate kinase (PK) showed positive scaling, with scaling coefficients ranging from +0.08 to +0.23. The ratio of mass-specific enzyme activity in PK to CS increased with body size, whereas the ratio of mRNA transcripts of PK to CS was unaffected, suggesting the enzyme relationships were not due simply to transcriptional regulation of both genes. The mass-dependent differences in PK activities were best explained by transcriptional regulation of the muscle PK gene; PK mRNA was a good predictor of PK specific enzyme activity within species and between species. Conversely, CS mRNA did not correlate with CS specific enzyme activities, suggesting post-transcriptional mechanisms may explain the observed inter-specific and intraspecific differences in oxidative enzymes. / Thesis (Master, Biology) -- Queen's University, 2007-10-31 11:55:28.757

Thesis (Ph.D.)--University of Tennessee Health Science Center, 2009. / Title from title page screen (viewed on July 22, 2009). Research advisor: Edwards A. Park. Document formatted into pages (xi, 94 p. : ill.). Vita. Abstract. Includes bibliographical references (p. 69-89).

Techn. University, Diss., 2000--Berlin.

Pyruvate kinase catalyses the final step in glycolysis and is responsible for net ATP production. There are four pyruvate kinase isoforms expressed in humans; LPYK, RPYK, M1PYK and M2PYK. The allosteric enzyme M2PYK plays an important role in cancer cell metabolism and is subject to complex regulation by numerous naturally occurring small-molecule metabolites. Post-translational modifications have also been found to play a key role in the regulation of M2PYK, among these cysteine oxidation. This thesis describes the production and characterisation of M2PYK cysteine point mutants in order to investigate the mechanism of regulation by cysteine modification. From a total of ten cysteines present in M2PYK, five were chosen for mutation based on a combination of the results from the cysteine oxidation prediction program (COPP) web interface and published experimental evidence for cysteine modification of M2PYK. Eight point mutants of these five cysteines were produced and characterised. Low resolution gel filtration of all the mutants shows that mutation of these cysteines has an effect on tetramer:dimer:monomer equilibrium of M2PYK suggesting that cysteine modifications could regulate M2PYK activity by affecting oligomeric state. Activity assays show that none of the cysteine point mutations are sufficient to protect M2PYK from oxidation by H2O2 indicating that more than one cysteine is involved in the regulation of M2PYK by oxidation. Nitric oxide (NO) imbalance has recently emerged as playing a key role in numerous diseases including cancer. NO regulates the function of target proteins through the addition of a nitroso moiety from NO-derived metabolites to a reactive cysteine, a process known as protein S-nitrosylation. M2PYK has been found to be S-nitrosylated in vivo. Using the biotin-switch assay in vitro combined with mass spectrometry I have shown that a likely candidate for the target of S-nitrosylation of M2PYK is C326. This thesis also describes the structures of two cysteine point mutants; M2PYK C424A and M2PYK C358S. The structures show that these mutations have very little effect on the overall conformation of M2PYK with only very subtle localised changes. The structure of the mutant M2PYK C358S shows some interesting features including varying occupation of the active site resulting in differing conformations of the B domains within the same tetramer, and an unusual B factor distribution which could be indicative of a perturbation in cooperativity within the tetramer caused by the mutation.

The effects of an increase in body temperature per se on the lactate and pyruvate concentrations of the arterial blood, muscle venous blood, sagittal sinus blood, and cerebrospinal fluid were determined. Paralysed anesthetized dogs with near normal arterial pH and PC0(2) values were ventilated with a 50% 0(2), 50% N(2) mixture and heated to a temperature of 42°C and maintained at this temperature for a period of 2 hours. During hyperthermia a slight increase in lactate and pyruvate was observed in the arterial blood. However, this was not statistically significant. Also a slight increase in the concentration of these substances occurred in the muscle venous blood and sagittal sinus blood. This change, however, was parallel to that observed in the arterial blood. The lactate-pyruvate ratio of the arterial blood, muscle venous blood and sagittal sinus blood did not show any significant change and thus no increase in anaerobic processes was detected during the hyperthermic period. On the other hand the cerebrospinal fluid lactate and pyruvate increased significantly throughout the hyperthermic period but maintained a constant lactate-pyruvate ratio. The results indicate that the increase of lactate and pyruvate in the cerebrospinal fluid are a result of an increased rate of aerobic glycolysis. The fact that the increases observed in the cerebrospinal fluid lactate and pyruvate were not reflected in the cerebral venous blood indicates lactate and pyruvate may have difficulty in diffusing across the blood brain barrier and cerebral venous blood is thus a poor index of cerebral lactate and pyruvate changes. / Medicine, Faculty of / Cellular and Physiological Sciences, Department of / Graduate

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22145号 / 医博第4536号 / 新制||医||1039(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 戸口田 淳也, 教授 安達 泰治, 教授 松田 秀一 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Mitochondrial DNA mutations accumulate with age and may play a role in stem cell aging as suggested by the premature aging phenotype of mitochondrial DNA polymerase gamma (POLG) exonuclease-deficient mice. Therefore, E1A immortalized murine embryonic fibroblasts (MEFs) from POLG exonuclease-deficient and wild-type (WT) mice were constructed. Surprisingly, when some E1A immortalized MEF lines were cultured in pyruvate-containing media they slowly became addicted to the pyruvate. The POLG exonuclease-deficient MEFs were more sensitive to several mitochondrial inhibitors and showed increased reactive oxygen species (ROS) production under standard conditions. When cultured in pyruvate-containing media, POLG exonuclease-deficient MEFs showed decreased oxygen consumption compared to controls. Increased AMP-activated protein kinase (AMPK) signaling and decreased mammalian target of rapamycin (mTOR) signaling delayed aging and influenced mitochondrial function. Therefore, the effects of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an AMPK activator, or rapamycin, an mTOR inhibitor, on measures of mitochondrial function were determined. Rapamycin treatment transiently increased respiration only in WT MEFs and, under most conditions, increased ATP levels. Short term AICAR treatment transiently increased ROS production and, under most conditions, decreased ATP levels. Chronic AICAR treatment decreased respiration and ROS production in WT MEFs. These results demonstrate the context-dependent effects of AICAR and rapamycin on mitochondrial function.

2-Chloroethyl ethyl sulfide (CEES) or half-mustard gas, a sulfur mustard (HD) analog, is a genotoxic agent that causes oxidative stress and induces both apoptotic and necrotic cell death. Sodium pyruvate induced a necrosis-to-apoptosis shift in HaCaT cells exposed to CEES levels ≥ 1.5 mmol/L and lowered markers of DNA damage, oxidative stress, and inflammation. This study provides a rationale for the future development of multicomponent therapies for HD toxicity in the skin. We hypothesize that a combination of pyruvates with scavengers/antioxidants encapsulated in liposomes for optimal local delivery should be therapeutically beneficial against HD-induced skin injury. However, the latter suggestion should be verified in animal models exposed to HD.

Dichloroacetate (DCA) is an investigational drug for the treatment of genetic mitochondrial diseases. Its primary site of action is the pyruvate dehydrogenase (PDH) complex, which it stimulates by altering its phosphorylation state and stability. DCA is metabolized by and inhibits the bifunctional zeta-1 family isoform of glutathione transferase/maleylacetoacetate isomerase. Polymorphic variants of this enzyme differ in their kinetic properties toward DCA, thereby influencing its biotransformation and toxicity, both of which are also influenced by subject age. Results from open label studies and controlled clinical trials suggest chronic oral DCA is generally well-tolerated by young children and may be particularly effective in patients with PDH deficiency. Recent in vitro data indicate that a combined DCA and gene therapy approach may also hold promise for the treatment of this devastating condition.